Belnacasan (VX-765, VX765)是VRT-043198的口服生物活性前药，一般被代谢为活性分子VRT-043198，是caspase-1选择性抑制剂，K_i值为0.8 nM。Caspase-1活化关键的炎性介质IL-1β，使其转换为有活性的分泌蛋白。Belnacasan可用于研究自身性炎症疾病，目前处于治疗银屑病和癫痫的II期临床试验中。

参考文献

1.Wannamaker W, et al. (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18. J Pharmacol Exp Ther. 2007 May;321(2):509-16.

2.Ravizza T, et al. Inactivation of caspase-1 in rodent brain: a novel anticonvulsive strategy. Neurobiol Dis. 2008 Sep;31(3):327-33.

3.Maroso M, et al. Interleukin-1β biosynthesis inhibition reduces acute seizures and drug resistant chronic epileptic activity in mice. Neurotherapeutics. 2011 Apr;8(2):304-15.

冰袋运输。粉末直接保存于-20℃，有效期3年。建议分装后-20℃干燥保存，避免反复冻融。